Profusa and Bio Insights amend asset purchase agreement; delete provision for 12% management share issuance

Profusa, Inc.

Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.
$30M purchase price for PanOmics multi-omics assay know-how, paid in Series A Convertible Preferred, unchanged.
Amendment confirms no other changes to the Asset Purchase Agreement remain in full force.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Profusa, Inc. entered into First Amendment to Asset Purchase Agreement with Bio Insights LLC valued at $30,000,000 (effective 2026-05-22).

Action: entry
Agreement: asset purchase
Counterparty: Bio Insights LLC
Value: $30,000,000
Effective: 2026-05-22

Exact text from the filing

On May 22, 2026, Profusa Inc., a Delaware corporation (the “Company”), and Bio Insights LLC, a limited liability company (“Seller”), entered into a First Amendment to the Asset Purchase Agreement (the “Amendment”), amending that certain Asset Purchase Agreement, dated as of April 21, 2026 (the “Asset Purchase Agreement”), by and between the Company and Seller.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Profusa, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-060879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.